AtriCure hails first-in-man implant of left atrial appendage occluder:
This article was originally published in Clinica
Executive Summary
AtriCure has, for the first time, implanted its CosGrove-Gillinov left atrial appendage (LAA) occlusion system into a patient. The LAA is a thumb-shaped area of the atrium that is prone to developing blood clots which can then migrate to other parts of the body. The product is a clip device designed to be implanted from outside the heart, thus avoiding contact with circulating blood and eliminating blood flow between the LAA and atria. Research has suggested that patients with atrial fibrillation are particularly prone to clot formation in the LAA, which some physicians believe is associated with AF-related strokes, claimed the West Chester, Ohio firm. The device was implanted during an open heart procedure by a team of doctors from the University of Zurich in Switzerland and Cleveland Clinic in Ohio.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.